^
Association details:
| Biomarker: | MYC rearrangement + BCL2 rearrangement |
|---|---|
| Cancer: | Lymphoma |
| Drug: | nab-paclitaxel/rituximab nanoparticle (AR160) (Bcl2 inhibitor, CD20 inhibitor, Tubulin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4471 A First in Human Phase I Trial (LS1681) of Abraxane/Rituximab 160 Nm Nanoparticle (AR160) in Relapsed Refractory B-Cell Lymphomas Including Transformed Follicular Lymphoma: A Final Report
Published date:
11/02/2023
Excerpt:
There were 6 partial responses (71%), 1 complete response (14%) with high-grade B-cell lymphoma with MYC and BCL2 rearrangement...AR160 therapy is a novel drug delivery system incorporating significantly lower doses of paclitaxel and rituximab that is safe and demonstrates promising clinical activity in patients with low-grade and high-grade previously treated B-cell lymphomas.
